THERAPY DOSSIER · th-95fb50c5d822

gamma-glutamylcysteine ethyl ester (GCEE)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21534958 ↗2011Reported benefit

gamma-glutamylcysteine ethyl ester protects cerebral endothelial cells during injury and decreases blood-brain barrier permeability after experimental brain trauma.

MouseTBIControlled cortical impactC57BL/6Maleintraperitoneal10 min after trauma

Model: controlled cortical impact brain trauma (with in vitro oxidative/OGD)

Post-trauma GCEE reduced acute blood-brain barrier permeability and protected brain endothelial cells against oxidative injury.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…